MRNS — Marinus Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- $30.34m
- $43.35m
- $30.99m
U.S. STOCKS ON THE MOVE-Broadcom, Xponential Fitness, Northfield Bancorp
U.S. STOCKS ON THE MOVE-Autodesk, Aaron's Company
Marinus down after seizure treatment fails to meet a key late-stage study goal
Brief: Marinus Pharmaceuticals Announces Topline Results from Phase 3 RAISE Trial of IV Ganaxolone in Refractory Status Epilepticus
Brief: Marinus Pharmaceuticals Enrollment Complete In Phase 3 Trusttsc Trial
U.S. RESEARCH ROUNDUP- Crescent Energy, Rockwell Automation, Transdigm Group
Marinus Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary
Marinus Pharmaceuticals Inc expected to post a loss of 66 cents a share - Earnings Preview
Marinus plunges as seizure drug fails to meet early stopping criteria for study
Brief: Marinus Pharmaceuticals Provides Update On The Phase 3 Raise Trial
Marinus sinks as seizure drug fails to meet early stopping criteria for study
U.S. STOCKS ON THE MOVE-Longeveron, Novavax, Telsa
Brief: Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Marinus Pharmaceuticals Says Co Will Defend Its Patents Amidst IPR Challenge From Ovid Therapeutics
Marinus Pharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary
Brief: Marinus Pharmaceuticals Provides Business Update And Reports Fourth Quarter And Full Year 2023 Financial Results
Marinus Pharmaceuticals Inc expected to post a loss of 62 cents a share - Earnings Preview
Brief: Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule